ArticleClinical Medicine Insights. Oncology2022

First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments.

Naifu Nie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.